Our Journals
Feature
Malaria deaths higher than previously thought
New data show that malaria mortality worldwide could be almost double that of previous estimates—at around 1.24 million deaths in 2010. The data, published in an Article, highlight how there could be many more deaths overall in young children, with implications for child survival programmes, and for older children and adults. An Editorial calls for urgent action to review these data and re-align priorities in malaria control. The issue is also discussed in a Podcast.
|
Selected Online First articles from The Lancet journals ahead of print publication.
|
Whistleblowers file suits against US FDA
News The Lancet Oncology (online February 3)
|
|
Suicide rates and mental health service recommendations
Article The Lancet (online February 2)
|
|
Depression in young people
Seminar The Lancet (online February 2)
|
-
Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort studyArticle The Lancet Neurology (online February 3)
-
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisArticle The Lancet Neurology (online February 3)
-
Multidisciplinary Head and Neck Cancer SymposiumNews The Lancet Oncology (online February 3)
-
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trialArticle The Lancet Neurology (online February 1)
-
Course of untreated cerebral cavernous malformationsArticle The Lancet Neurology (online January 31)
-
Postoperative antibioticsArticle The Lancet Infectious Diseases (online January 31)
The Lancet's summary of
news and developments across medicine
This Week in Medicine represents a snapshot of important, interesting, and sometimes quirky health-related happenings from around the world reported in the past week or so.
This up-to-date content is free to all our users.
Making the most of evaluation
Papers published on The Lancet UK Policy Matters microsite raise concerns about the quality of past evaluations commissioned directly or indirectly by the Department of Health. Read the papers and accompanying blog post to find out more.
About UK Policy Matters
UK Policy Matters is a Lancet-based project which explores how UK policy changes affect health. On our microsite you will be able to access evidence-based summaries of different policies and tell us your experiences of how changes in policy have affected health.
How can you help?
If you have evidence of how policy has affected health or health care, we would like to hear from you. We are interested in all forms of evidence, including brief summaries of evidence from academics; and information from the public, managers, and healthcare workers about changes in services and their impact (individual experiences are welcomed).
See the Submit your evidence section of the site to share your experiences and submit your evidence.
Most read in The Lancet journals in December 2011
| 1. |
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial
Article
(2011)
The Lancet
378
(9808), pp.
2013-2020
|
| 2. |
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Article
(2012)
The Lancet Infectious Diseases
12
(1), pp.
36-44
|
| 3. |
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
Article
(2011)
The Lancet
378
(9809), pp.
2081-2087
|
| 4. |
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
Article
(2011)
The Lancet
Online December 1, 2011
|
| 5. |
The plight of nuns: hazards of nulliparity
Comment
(2011)
The Lancet
Online December 8, 2011
|
Most cited in The Lancet since 1996
| 1. | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Research (1998) Lancet 352 (9131), pp. 837-853
|
| 2. | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial
Research (2002) Lancet 360 (9326), pp. 7-22
|
| 3. | Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Research (1998) Lancet 351 (9118), pp. 1755-1762
|
| 4. | Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
Research (2001) Lancet 358 (9286), pp. 958-965
|
| 5. | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
Research (1996) Lancet 348 (9038), pp. 1329-1339
|
|
Join The Lancet Student for free content |
|
Find us on Facebook |
|
Follow us on Twitter |
AnnouncementsLatest Clinical Video: homozygous familial hypercholesterolaemia The Lancet Middle East Editorial Page: antibiotic misuse and antibiotic-resistant bacteria. The Lancet iPad App: now available in the iTunes App Store. TB Symposium: action on the social determinants of tuberculosis, Feb 15, 2012 at the LSHTM. Transformative education for global health: Feb 15, 2012, Institute of Child Health, UCL, London. Open to all. See also The Lancet Commission. |
A 5-year-old boy affected with homozygous familial hypercholesterolaemia, diagnosed aged 1 year, was referred to us after having an acute ischaemic cardiac event. He presented with an LDL-cholesterol concentration of 26 mmol/L, and tendon xanthomas at the wrists, knees, and achilles. He had been treated with colestyramine. Coronary angiography showed a complete obstruction of the left coronary artery and a partial obstruction of the right coronary artery, which required stent placement.
View Clinical Picture
Letter to the Editor
"There was nothing useful to be gained by identifying the 'best' of generally unacceptable therapies, and such 'spin' on a failed study could potentially harm patients if followed blindly."
Listen to summaries of The Lancet journals in mp3 format
Latest video highlights from the At the Limits events
Cardiology & Diabetes at the Limits
The "Code of Practice" - when will the limits be reached?
Nephrology at the Limits
Consequences of HIV infection in South Africa
Oncology at the Limits
Lessons from acute myeloid leukaemia
